Search company, investor...
Genomic Health company logo

Genomic Health

Founded Year



Acq - P2P | Acquired

Total Raised




About Genomic Health

Genomic Health is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Headquarters Location

101 Galveston Drive

Redwood City, California, 94063,

United States


Missing: Genomic Health's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genomic Health's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Genomic Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genomic Health is included in 2 Expert Collections, including Cancer.



105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Genomic Health Patents

Genomic Health has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Molecular biology
  • Oncology
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Proteins, Molecular biology, Gene expression


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Proteins, Molecular biology, Gene expression



Latest Genomic Health News

North American Companion Diagnostics Industry to 2028 - Featuring Danaher, GE Healthcare, Genomic Health and Illumina Among Others -

Sep 29, 2022

According to this report the companion diagnostics market in North America is evaluated to attain a compound annual growth rate of 12.96% over the forecasting years 2022 to 2028. The United States and Canada shape the market in the region. In Canada, several public and private initiatives are expected to widen the scope of the studied market, despite limited healthcare policy. For instance, the Alliance for Innovation in Molecular Diagnostics is working to improve the companion diagnostics innovation environment. The initiatives also aim to decrease the lack of clarity on how decision-makers prioritize the CDx tests by highlighting the interprovincial regulations that deter CDx development and adoption. Furthermore, HTA agencies, government agencies, and hospitals strive to promote CDx applications by providing reimbursements. Above all, innovative clinical trials, increased R&D investments, and healthcare plans are anticipated to fuel the Canadian companion diagnostics market's growth over the forecast period. In the US, the rapid evolution of diagnostics technologies and investments are increasing the demand for advanced diagnostic testing. Moreover, the recent developments favoring comprehensive CDx tests to gain the necessary information to make therapeutic decisions are responsible for propelling the companion diagnostics market on a growth path. Companies Mentioned

Genomic Health Frequently Asked Questions (FAQ)

  • When was Genomic Health founded?

    Genomic Health was founded in 2000.

  • Where is Genomic Health's headquarters?

    Genomic Health's headquarters is located at 101 Galveston Drive, Redwood City.

  • What is Genomic Health's latest funding round?

    Genomic Health's latest funding round is Acq - P2P.

  • How much did Genomic Health raise?

    Genomic Health raised a total of $117.64M.

  • Who are the investors of Genomic Health?

    Investors of Genomic Health include Exact Sciences, Kleiner Perkins Caufield & Byers, TPG Biotech, Integral Capital Partners, J.P. Morgan Chase & Co. and 8 more.

  • Who are Genomic Health's competitors?

    Competitors of Genomic Health include CirculoGene Diagnostics, SimBioSys, Stratipath, Auspex, Guardant Health and 8 more.

Compare Genomic Health to Competitors

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. Its Breath Biopsy platform enables early detection across multiple cancers and a range of other conditions. Breath Biopsy can also be used to enable precision medicine, ensuring that the right drug is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs. The company was founded in 2004 and is based in Cambridge, England.

CirculoGene Diagnostics

Circulogene is a personalized medicine company that is developing a "liquid biopsy" that is based on the discovery that as tumors grow, they also die, releasing their DNA into the bloodstream. Circulogene's liquid biopsy tumor DNA sequencing is a test that aims to combine finger-stick volumes of blood and next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes. The company was founded in 2015 and is based in Birmingham, Alabama.

OncoTAB Logo

OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.

Freenome Logo

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.


Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.